JP2011513374A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011513374A5 JP2011513374A5 JP2010549188A JP2010549188A JP2011513374A5 JP 2011513374 A5 JP2011513374 A5 JP 2011513374A5 JP 2010549188 A JP2010549188 A JP 2010549188A JP 2010549188 A JP2010549188 A JP 2010549188A JP 2011513374 A5 JP2011513374 A5 JP 2011513374A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- yloxy
- carboxylic acid
- azetidine
- pyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 12
- -1 chloro, fluoro, bromo, cyclopropyl Chemical group 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 208000002193 Pain Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000006413 ring segment Chemical group 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 claims 2
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 2
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims 2
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 2
- LFMYRGYJZXJAQA-UHFFFAOYSA-N 1-[3-[5-[2-chloro-5-(2-methoxyethoxy)phenyl]pyridin-2-yl]oxyazetidin-1-yl]-2-pyridazin-3-ylethanone Chemical compound COCCOC1=CC=C(Cl)C(C=2C=NC(OC3CN(C3)C(=O)CC=3N=NC=CC=3)=CC=2)=C1 LFMYRGYJZXJAQA-UHFFFAOYSA-N 0.000 claims 1
- OJNMDFAPRGQGBO-UHFFFAOYSA-N 3-(4-phenylphenoxy)-n-pyridin-3-ylazetidine-1-carboxamide Chemical compound C1C(OC=2C=CC(=CC=2)C=2C=CC=CC=2)CN1C(=O)NC1=CC=CN=C1 OJNMDFAPRGQGBO-UHFFFAOYSA-N 0.000 claims 1
- VSQUREFTKYDATG-UHFFFAOYSA-N 3-(5-phenylpyridin-2-yl)oxy-n-pyridazin-3-ylazetidine-1-carboxamide Chemical compound C1C(OC=2N=CC(=CC=2)C=2C=CC=CC=2)CN1C(=O)NC1=CC=CN=N1 VSQUREFTKYDATG-UHFFFAOYSA-N 0.000 claims 1
- JQWUVQIJUMPKBT-UHFFFAOYSA-N 3-[5-(2,5-dimethoxyphenyl)pyridin-2-yl]oxy-n-pyridazin-3-ylazetidine-1-carboxamide Chemical compound COC1=CC=C(OC)C(C=2C=NC(OC3CN(C3)C(=O)NC=3N=NC=CC=3)=CC=2)=C1 JQWUVQIJUMPKBT-UHFFFAOYSA-N 0.000 claims 1
- BYDXKBRWKDOLGO-UHFFFAOYSA-N 3-[5-(2,6-difluorophenyl)pyridin-2-yl]oxy-n-pyridazin-3-ylazetidine-1-carboxamide Chemical compound FC1=CC=CC(F)=C1C(C=N1)=CC=C1OC1CN(C(=O)NC=2N=NC=CC=2)C1 BYDXKBRWKDOLGO-UHFFFAOYSA-N 0.000 claims 1
- GQVNLDQKGBHOIC-UHFFFAOYSA-N 3-[5-(2-fluoro-3-methoxyphenyl)pyridin-2-yl]oxy-n-pyridazin-3-ylazetidine-1-carboxamide Chemical compound COC1=CC=CC(C=2C=NC(OC3CN(C3)C(=O)NC=3N=NC=CC=3)=CC=2)=C1F GQVNLDQKGBHOIC-UHFFFAOYSA-N 0.000 claims 1
- KNBDOAMGXZNPNC-UHFFFAOYSA-N 3-[5-(2-fluorophenyl)pyridin-2-yl]oxy-n-(5-methyl-1,3,4-oxadiazol-2-yl)azetidine-1-carboxamide Chemical compound O1C(C)=NN=C1NC(=O)N1CC(OC=2N=CC(=CC=2)C=2C(=CC=CC=2)F)C1 KNBDOAMGXZNPNC-UHFFFAOYSA-N 0.000 claims 1
- CAOQMJUAAURBJS-UHFFFAOYSA-N 3-[5-(2-fluorophenyl)pyridin-2-yl]oxy-n-(5-methylpyridazin-3-yl)azetidine-1-carboxamide Chemical compound CC1=CN=NC(NC(=O)N2CC(C2)OC=2N=CC(=CC=2)C=2C(=CC=CC=2)F)=C1 CAOQMJUAAURBJS-UHFFFAOYSA-N 0.000 claims 1
- WDSQRLGJMFXFHS-UHFFFAOYSA-N 3-[5-(2-fluorophenyl)pyridin-2-yl]oxy-n-(6-methoxypyridazin-3-yl)azetidine-1-carboxamide Chemical compound N1=NC(OC)=CC=C1NC(=O)N1CC(OC=2N=CC(=CC=2)C=2C(=CC=CC=2)F)C1 WDSQRLGJMFXFHS-UHFFFAOYSA-N 0.000 claims 1
- MXZUCQMCGWGEFM-UHFFFAOYSA-N 3-[5-(2-fluorophenyl)pyridin-2-yl]oxy-n-pyrazin-2-ylazetidine-1-carboxamide Chemical compound FC1=CC=CC=C1C(C=N1)=CC=C1OC1CN(C(=O)NC=2N=CC=NC=2)C1 MXZUCQMCGWGEFM-UHFFFAOYSA-N 0.000 claims 1
- LIPUUWBEFCDHSI-UHFFFAOYSA-N 3-[5-(2-fluorophenyl)pyridin-2-yl]oxy-n-pyridazin-3-ylazetidine-1-carboxamide Chemical compound FC1=CC=CC=C1C(C=N1)=CC=C1OC1CN(C(=O)NC=2N=NC=CC=2)C1 LIPUUWBEFCDHSI-UHFFFAOYSA-N 0.000 claims 1
- MIFBPPGNFILKGT-UHFFFAOYSA-N 3-[5-(2-fluorophenyl)pyridin-2-yl]oxy-n-pyridazin-4-ylazetidine-1-carboxamide Chemical compound FC1=CC=CC=C1C(C=N1)=CC=C1OC1CN(C(=O)NC=2C=NN=CC=2)C1 MIFBPPGNFILKGT-UHFFFAOYSA-N 0.000 claims 1
- MTFOKLQRMIRECU-UHFFFAOYSA-N 3-[5-(2-fluorophenyl)pyridin-2-yl]oxyazetidine-1-carboxylic acid Chemical compound C1N(C(=O)O)CC1OC1=CC=C(C=2C(=CC=CC=2)F)C=N1 MTFOKLQRMIRECU-UHFFFAOYSA-N 0.000 claims 1
- UXHHUYMCPZQNPI-UHFFFAOYSA-N 3-[5-(2-methoxyphenyl)pyridin-2-yl]oxyazetidine-1-carboxylic acid;pyridazin-3-amine Chemical compound NC1=CC=CN=N1.COC1=CC=CC=C1C(C=N1)=CC=C1OC1CN(C(O)=O)C1 UXHHUYMCPZQNPI-UHFFFAOYSA-N 0.000 claims 1
- YNZXNGQXSSMPCL-UHFFFAOYSA-N 3-[5-[2-methoxy-5-(2-methoxyethoxy)phenyl]pyridin-2-yl]oxy-n-pyridazin-3-ylazetidine-1-carboxamide Chemical compound COCCOC1=CC=C(OC)C(C=2C=NC(OC3CN(C3)C(=O)NC=3N=NC=CC=3)=CC=2)=C1 YNZXNGQXSSMPCL-UHFFFAOYSA-N 0.000 claims 1
- RUVJJFSFPPMCNM-UHFFFAOYSA-N 3-[5-[3-(2-hydroxyethoxy)phenyl]pyridin-2-yl]oxy-n-pyridazin-3-ylazetidine-1-carboxamide Chemical compound OCCOC1=CC=CC(C=2C=NC(OC3CN(C3)C(=O)NC=3N=NC=CC=3)=CC=2)=C1 RUVJJFSFPPMCNM-UHFFFAOYSA-N 0.000 claims 1
- PJLSNOYLAQEJLZ-UHFFFAOYSA-N 3-[5-[3-(2-methoxyethoxy)phenyl]pyridin-2-yl]oxy-n-pyrazin-2-ylazetidine-1-carboxamide Chemical compound COCCOC1=CC=CC(C=2C=NC(OC3CN(C3)C(=O)NC=3N=CC=NC=3)=CC=2)=C1 PJLSNOYLAQEJLZ-UHFFFAOYSA-N 0.000 claims 1
- JKZDNQWCCLHQNS-UHFFFAOYSA-N 3-[5-[3-(2-methoxyethoxy)phenyl]pyridin-2-yl]oxy-n-pyridazin-3-ylazetidine-1-carboxamide Chemical compound COCCOC1=CC=CC(C=2C=NC(OC3CN(C3)C(=O)NC=3N=NC=CC=3)=CC=2)=C1 JKZDNQWCCLHQNS-UHFFFAOYSA-N 0.000 claims 1
- KUYLWYGIJNQGJB-UHFFFAOYSA-N 3-[5-[3-(2-methoxyethoxy)phenyl]pyridin-2-yl]oxy-n-pyridin-3-ylazetidine-1-carboxamide Chemical compound COCCOC1=CC=CC(C=2C=NC(OC3CN(C3)C(=O)NC=3C=NC=CC=3)=CC=2)=C1 KUYLWYGIJNQGJB-UHFFFAOYSA-N 0.000 claims 1
- XWQAAAKUKBKZNR-UHFFFAOYSA-N 3-[5-[3-(2-methoxyethoxy)phenyl]pyridin-2-yl]oxy-n-pyrimidin-4-ylazetidine-1-carboxamide Chemical compound COCCOC1=CC=CC(C=2C=NC(OC3CN(C3)C(=O)NC=3N=CN=CC=3)=CC=2)=C1 XWQAAAKUKBKZNR-UHFFFAOYSA-N 0.000 claims 1
- KWGBRFMUYCLMJO-UHFFFAOYSA-N 3-[5-[3-(2-phenylmethoxyethoxy)phenyl]pyridin-2-yl]oxy-n-pyridazin-3-ylazetidine-1-carboxamide Chemical compound C1C(OC=2N=CC(=CC=2)C=2C=C(OCCOCC=3C=CC=CC=3)C=CC=2)CN1C(=O)NC1=CC=CN=N1 KWGBRFMUYCLMJO-UHFFFAOYSA-N 0.000 claims 1
- KAZMCIGKULUUMR-UHFFFAOYSA-N 6-methylpyridazin-3-amine Chemical compound CC1=CC=C(N)N=N1 KAZMCIGKULUUMR-UHFFFAOYSA-N 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 102100027297 Fatty acid 2-hydroxylase Human genes 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 101000937693 Homo sapiens Fatty acid 2-hydroxylase Proteins 0.000 claims 1
- 101000918494 Homo sapiens Fatty-acid amide hydrolase 1 Proteins 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010063897 Renal ischaemia Diseases 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 208000002173 dizziness Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 125000005549 heteroarylene group Chemical group 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- OYKNEKYHRLBMTC-UHFFFAOYSA-N n-(2-fluorophenyl)-3-(4-phenylphenoxy)azetidine-1-carboxamide Chemical compound FC1=CC=CC=C1NC(=O)N1CC(OC=2C=CC(=CC=2)C=2C=CC=CC=2)C1 OYKNEKYHRLBMTC-UHFFFAOYSA-N 0.000 claims 1
- HFEFMQVTVZOJLC-UHFFFAOYSA-N n-(3-fluorophenyl)-3-(4-phenylphenoxy)azetidine-1-carboxamide Chemical compound FC1=CC=CC(NC(=O)N2CC(C2)OC=2C=CC(=CC=2)C=2C=CC=CC=2)=C1 HFEFMQVTVZOJLC-UHFFFAOYSA-N 0.000 claims 1
- PQSZLQWHLSSGQC-UHFFFAOYSA-N n-phenyl-3-(4-phenylphenoxy)azetidine-1-carboxamide Chemical compound C1C(OC=2C=CC(=CC=2)C=2C=CC=CC=2)CN1C(=O)NC1=CC=CC=C1 PQSZLQWHLSSGQC-UHFFFAOYSA-N 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 244000045947 parasite Species 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000005551 pyridylene group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0804006.5A GB0804006D0 (en) | 2008-03-04 | 2008-03-04 | Azetidine derivatives |
| GB0804006.5 | 2008-03-04 | ||
| GB0821694.7 | 2008-11-27 | ||
| GBGB0821694.7A GB0821694D0 (en) | 2008-11-27 | 2008-11-27 | Azetidine derivatives |
| PCT/GB2009/000568 WO2009109743A1 (en) | 2008-03-04 | 2009-02-27 | Azetidine derivatives |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014198461A Division JP5986163B2 (ja) | 2008-03-04 | 2014-09-29 | アゼチジン誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011513374A JP2011513374A (ja) | 2011-04-28 |
| JP2011513374A5 true JP2011513374A5 (enExample) | 2012-03-29 |
| JP5624894B2 JP5624894B2 (ja) | 2014-11-12 |
Family
ID=40613126
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010549188A Active JP5624894B2 (ja) | 2008-03-04 | 2009-02-27 | アゼチジン誘導体 |
| JP2014198461A Active JP5986163B2 (ja) | 2008-03-04 | 2014-09-29 | アゼチジン誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014198461A Active JP5986163B2 (ja) | 2008-03-04 | 2014-09-29 | アゼチジン誘導体 |
Country Status (18)
| Country | Link |
|---|---|
| US (6) | US8450346B2 (enExample) |
| EP (1) | EP2265578B1 (enExample) |
| JP (2) | JP5624894B2 (enExample) |
| CN (1) | CN102015635B (enExample) |
| AU (1) | AU2009220974B2 (enExample) |
| BR (1) | BRPI0909782B8 (enExample) |
| CA (1) | CA2717750C (enExample) |
| DK (1) | DK2265578T3 (enExample) |
| EA (1) | EA017842B1 (enExample) |
| ES (1) | ES2550367T3 (enExample) |
| HU (1) | HUE025411T2 (enExample) |
| IL (1) | IL207768A (enExample) |
| MX (1) | MX2010009658A (enExample) |
| NZ (1) | NZ587532A (enExample) |
| PL (1) | PL2265578T3 (enExample) |
| PT (1) | PT2265578E (enExample) |
| WO (1) | WO2009109743A1 (enExample) |
| ZA (1) | ZA201006270B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2265578T3 (en) * | 2008-03-04 | 2015-10-12 | Vernalis R&D Ltd | Azetidin-DERIVATIVES |
| WO2011085216A2 (en) | 2010-01-08 | 2011-07-14 | Ironwood Pharmaceuticals, Inc. | Use of faah inhibitors for treating parkinson's disease and restless legs syndrome |
| US20130224151A1 (en) | 2010-03-31 | 2013-08-29 | United States Of America | Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain |
| KR101273566B1 (ko) | 2011-09-05 | 2013-06-11 | 한국과학기술연구원 | 신규한 아제티딘 유도체 및 이를 함유하는 항우울제 조성물 |
| PT2800738T (pt) * | 2012-01-06 | 2020-06-23 | Novartis Ag | Compostos heterocíclicos e métodos para a utilização dos mesmos |
| WO2016014975A2 (en) | 2014-07-25 | 2016-01-28 | Northeastern University | Urea/carbamates faah magl or dual faah/magl inhibitors and uses thereof |
| JOP20190072A1 (ar) * | 2016-10-13 | 2019-04-07 | Glaxosmithkline Ip Dev Ltd | مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم |
| US11660287B2 (en) * | 2017-06-02 | 2023-05-30 | Fujifilm Toyama Chemical Co., Ltd. | Agent for preventing or treating spinocerebellar ataxia |
| MX393052B (es) | 2017-06-02 | 2025-03-24 | Fujifilm Toyama Chemical Co Ltd | Agente para prevenir o tratar atrofia cerebral. |
| WO2018221731A1 (ja) * | 2017-06-02 | 2018-12-06 | 富山化学工業株式会社 | タウオパチー予防または治療剤 |
| EP3636262A4 (en) | 2017-06-02 | 2020-06-10 | FUJIFILM Toyama Chemical Co., Ltd. | AGENT FOR PREVENTING OR TREATING ALZHEIMER-LIKE DEMENTIA |
| BR112019024983A2 (pt) * | 2017-06-02 | 2020-06-23 | Fujifilm Toyama Chemical Co., Ltd. | Agente para reduzir a quantidade de proteína b amiloide |
| EP3705121B1 (en) | 2017-10-30 | 2023-08-30 | FUJIFILM Toyama Chemical Co., Ltd. | Emopamil binding protein binding agent and use thereof |
| US20240180905A1 (en) * | 2020-07-21 | 2024-06-06 | Neuritek Ltd. | Uses of fatty acid amide hydrolase inhibitors in treatment of trauma related psychiatric disorders |
| CN112374984A (zh) * | 2020-11-06 | 2021-02-19 | 苏州求索生物科技有限公司 | 一种2-溴-4-羟基苯甲醚的制备工艺 |
| US11141404B1 (en) | 2020-11-18 | 2021-10-12 | Anebulo Pharmaceuticals, Inc. | Formulations and methods for treating acute cannabinoid overdose |
| AU2022362107A1 (en) | 2021-10-11 | 2024-05-02 | Anebulo Pharmaceuticals, Inc. | Crystalline forms of a cannabinoid receptor type 1 (cb1) modulator and methods of use and preparation thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5183902A (en) * | 1985-02-28 | 1993-02-02 | A. H. Robins Company, Incorporated | Method of treating muscular tension, muscle spasticity and anxiety with 3-aryloxy and 3-arylthioazetidinecarboxamides |
| IN162808B (enExample) * | 1985-02-28 | 1988-07-09 | Robins Co Inc A H | |
| US6335445B1 (en) * | 1997-03-24 | 2002-01-01 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | Derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them |
| GB9801501D0 (en) * | 1998-01-23 | 1998-03-18 | Cerebrus Ltd | Chemical compounds - II |
| FR2866884B1 (fr) * | 2004-02-26 | 2007-08-31 | Sanofi Synthelabo | Derives d'aryl-et d'heteroaryl-piperidinecarboxylates, leur preparation et leur application en therapeutique |
| DK2265578T3 (en) * | 2008-03-04 | 2015-10-12 | Vernalis R&D Ltd | Azetidin-DERIVATIVES |
-
2009
- 2009-02-27 DK DK09716712.6T patent/DK2265578T3/en active
- 2009-02-27 PT PT97167126T patent/PT2265578E/pt unknown
- 2009-02-27 EA EA201001414A patent/EA017842B1/ru not_active IP Right Cessation
- 2009-02-27 WO PCT/GB2009/000568 patent/WO2009109743A1/en not_active Ceased
- 2009-02-27 CN CN2009801079287A patent/CN102015635B/zh active Active
- 2009-02-27 PL PL09716712T patent/PL2265578T3/pl unknown
- 2009-02-27 NZ NZ587532A patent/NZ587532A/en unknown
- 2009-02-27 ES ES09716712.6T patent/ES2550367T3/es active Active
- 2009-02-27 CA CA2717750A patent/CA2717750C/en active Active
- 2009-02-27 JP JP2010549188A patent/JP5624894B2/ja active Active
- 2009-02-27 MX MX2010009658A patent/MX2010009658A/es active IP Right Grant
- 2009-02-27 AU AU2009220974A patent/AU2009220974B2/en active Active
- 2009-02-27 BR BRPI0909782A patent/BRPI0909782B8/pt active IP Right Grant
- 2009-02-27 HU HUE09716712A patent/HUE025411T2/en unknown
- 2009-02-27 US US12/920,181 patent/US8450346B2/en active Active
- 2009-02-27 EP EP09716712.6A patent/EP2265578B1/en active Active
-
2010
- 2010-08-24 IL IL207768A patent/IL207768A/en active IP Right Grant
- 2010-09-01 ZA ZA2010/06270A patent/ZA201006270B/en unknown
-
2013
- 2013-04-19 US US13/866,059 patent/US9006269B2/en active Active
-
2014
- 2014-09-29 JP JP2014198461A patent/JP5986163B2/ja active Active
-
2015
- 2015-03-09 US US14/641,783 patent/US9475800B2/en active Active
-
2016
- 2016-09-28 US US15/278,386 patent/US10383871B2/en active Active
-
2019
- 2019-07-09 US US16/506,225 patent/US10918640B2/en active Active
-
2021
- 2021-01-14 US US17/148,785 patent/US12246014B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011513374A5 (enExample) | ||
| JP2009510043A5 (enExample) | ||
| CN104334529B (zh) | 用于抑制abl1、abl2和bcr‑abl1的活性的化合物和组合物 | |
| JP5985611B2 (ja) | 炎症および免疫関連用途のための化合物 | |
| JP2009536197A5 (enExample) | ||
| TWI241295B (en) | Pyridazine derivative and medicine containing the same as effect component | |
| JP2010508288A5 (enExample) | ||
| JP2011502982A5 (enExample) | ||
| JP2013542937A5 (enExample) | ||
| JP2007529484A5 (enExample) | ||
| JP2010513438A5 (enExample) | ||
| JP2009533410A5 (enExample) | ||
| WO2009114993A1 (zh) | 一类哒嗪酮类化合物及其制备方法和用途 | |
| JP2012526107A5 (enExample) | ||
| JP2008513515A5 (enExample) | ||
| JP2015531774A5 (enExample) | ||
| JP2011519854A5 (enExample) | ||
| JP2016500063A5 (enExample) | ||
| ME02047B (me) | Nova jedinjenja koja se vezuju za fxr (nr1 h4) i moduliraju njegovu aktivnost | |
| JP2013529210A5 (enExample) | ||
| JP2012504141A5 (enExample) | ||
| JP2010502615A (ja) | ５−リポキシゲナーゼ活性化タンパク質（ｆｌａｐ）の阻害剤 | |
| JP2008513504A5 (enExample) | ||
| JP2010504344A5 (enExample) | ||
| JP2009533435A (ja) | ジアリール置換アルカン |